

REMARKS

Claims 1, 4-7 and 9 are now allowed.


Claim 9 is amended to correct the claim format.

Claim 10 is added. Claim 10 is a duplicate of claim 2 that was cancelled by the Examiner's amendment included in the Notice of Allowance. The undersigned attorney representing Applicants had a few telephone conversations with the Examiner regarding the cancellation of claim 2. The Examiner agreed that claim 2 should not have been cancelled and suggested Applicants to file the above amendment, i.e., adding claim 10 to the claim list.

Applicants submit that the above amendment to the claims does not introduce new matter. Applicants respectfully request entry of the amendments such that the corrections are noted with the issuance of the patent.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. **18-1982** in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,



Jiang Lin, Reg. No. 51,065
Attorney for Applicants

Date: November 3, 2006

sanofi-aventis U.S. LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

sanofi-aventis Docket No.: DEAV2002-0058 US NP